Primary |
Atrial Fibrillation |
23.0% |
Product Used For Unknown Indication |
18.7% |
Cerebrovascular Accident Prophylaxis |
18.3% |
Thrombosis Prophylaxis |
10.7% |
Deep Vein Thrombosis |
4.9% |
Knee Arthroplasty |
4.3% |
Hypertension |
3.6% |
Pulmonary Embolism |
2.4% |
Hip Arthroplasty |
2.3% |
Embolism Venous |
2.2% |
Ill-defined Disorder |
1.4% |
Pain |
1.3% |
Blood Pressure |
1.1% |
Cardiac Disorder |
1.1% |
Thrombosis |
1.1% |
Anticoagulant Therapy |
0.9% |
Diabetes Mellitus |
0.7% |
Prophylaxis |
0.7% |
Orthopedic Procedure |
0.7% |
Knee Operation |
0.6% |
|
Pulmonary Embolism |
23.2% |
Deep Vein Thrombosis |
11.8% |
Thrombosis |
7.4% |
Cerebrovascular Accident |
6.8% |
Gastrointestinal Haemorrhage |
6.7% |
Haemorrhage |
5.5% |
Haemorrhage Intracranial |
4.8% |
Haemoglobin Decreased |
4.1% |
Drug Ineffective |
3.8% |
Death |
3.0% |
Ischaemic Stroke |
2.8% |
Thrombocytopenia |
2.6% |
Transient Ischaemic Attack |
2.5% |
Haematoma |
2.4% |
International Normalised Ratio Increased |
2.3% |
Rectal Haemorrhage |
2.2% |
Subdural Haematoma |
2.0% |
Cerebral Haemorrhage |
2.0% |
Renal Impairment |
2.0% |
Vomiting |
2.0% |
|
Secondary |
Atrial Fibrillation |
26.6% |
Cerebrovascular Accident Prophylaxis |
23.6% |
Product Used For Unknown Indication |
10.6% |
Thrombosis Prophylaxis |
10.1% |
Deep Vein Thrombosis |
5.1% |
Knee Arthroplasty |
4.3% |
Embolism Venous |
3.7% |
Hypertension |
3.3% |
Pulmonary Embolism |
2.6% |
Hip Arthroplasty |
2.1% |
Pain |
1.4% |
Thrombosis |
1.3% |
Blood Pressure |
1.0% |
Cardiac Disorder |
0.8% |
Anticoagulant Therapy |
0.7% |
Prophylaxis |
0.7% |
Diabetes Mellitus |
0.6% |
Cerebrovascular Accident |
0.5% |
Blood Cholesterol |
0.5% |
Cardiac Failure |
0.5% |
|
Pulmonary Embolism |
20.2% |
Deep Vein Thrombosis |
11.2% |
Thrombosis |
7.5% |
Gastrointestinal Haemorrhage |
6.7% |
Drug Ineffective |
6.4% |
Cerebrovascular Accident |
5.6% |
Haemoglobin Decreased |
4.3% |
Haemorrhage Intracranial |
3.9% |
Renal Impairment |
3.6% |
Thrombocytopenia |
3.4% |
Ischaemic Stroke |
3.3% |
Haemorrhage |
3.2% |
Haematoma |
3.1% |
Transient Ischaemic Attack |
3.0% |
Rectal Haemorrhage |
2.6% |
Subdural Haematoma |
2.5% |
Melaena |
2.4% |
Renal Failure Acute |
2.4% |
Vomiting |
2.4% |
International Normalised Ratio Increased |
2.2% |
|
Concomitant |
Product Used For Unknown Indication |
45.1% |
Atrial Fibrillation |
10.2% |
Hypertension |
8.5% |
Rheumatoid Arthritis |
4.6% |
Pain |
3.7% |
Anticoagulant Therapy |
3.1% |
Diabetes Mellitus |
2.4% |
Prophylaxis |
2.3% |
Cardiac Disorder |
2.2% |
Thrombosis Prophylaxis |
2.2% |
Cardiac Failure |
2.1% |
Blood Cholesterol Increased |
2.0% |
Pulmonary Embolism |
1.9% |
Deep Vein Thrombosis |
1.6% |
Depression |
1.5% |
Asthma |
1.4% |
Cardiac Failure Chronic |
1.4% |
Chronic Obstructive Pulmonary Disease |
1.4% |
Arrhythmia |
1.3% |
Plasma Cell Myeloma |
1.2% |
|
Vomiting |
9.2% |
Thrombosis |
7.9% |
Renal Failure Acute |
7.2% |
Weight Decreased |
7.2% |
Death |
5.9% |
Pneumonia |
5.9% |
Hepatitis Acute |
5.3% |
Nausea |
5.3% |
Syncope |
5.3% |
Atrial Fibrillation |
4.6% |
Pain |
4.6% |
Pulmonary Embolism |
3.9% |
Tremor |
3.9% |
Weight Increased |
3.9% |
Headache |
3.3% |
Oedema Peripheral |
3.3% |
Off Label Use |
3.3% |
Pruritus |
3.3% |
Tachycardia |
3.3% |
Wrist Deformity |
3.3% |
|
Interacting |
Atrial Fibrillation |
23.7% |
Cerebrovascular Accident Prophylaxis |
23.3% |
Product Used For Unknown Indication |
17.0% |
Thrombosis Prophylaxis |
5.8% |
Hypertension |
3.8% |
Cardiac Disorder |
3.4% |
Pain |
2.5% |
Blood Pressure Abnormal |
2.4% |
Hip Arthroplasty |
2.1% |
Prophylaxis |
2.0% |
Anticoagulant Therapy |
1.7% |
Antiplatelet Therapy |
1.5% |
Knee Arthroplasty |
1.5% |
Diuretic Therapy |
1.5% |
Coronary Artery Disease |
1.4% |
Diabetes Mellitus |
1.4% |
Ill-defined Disorder |
1.4% |
Blood Cholesterol Abnormal |
1.3% |
Atrial Flutter |
1.2% |
Stent Placement |
1.2% |
|
Gastrointestinal Haemorrhage |
16.3% |
Haemorrhage |
12.4% |
Rectal Haemorrhage |
6.9% |
Product Quality Issue |
5.9% |
Haemoglobin Decreased |
5.4% |
Haematochezia |
5.0% |
Haematuria |
4.5% |
Haemorrhage Intracranial |
4.5% |
International Normalised Ratio Increased |
4.5% |
Melaena |
4.5% |
Subdural Haematoma |
4.0% |
Blood Urine Present |
3.5% |
Drug Interaction |
3.0% |
Inappropriate Schedule Of Drug Administration |
3.0% |
Occult Blood Positive |
3.0% |
Prothrombin Time Prolonged |
3.0% |
Upper Gastrointestinal Haemorrhage |
3.0% |
Vaginal Haemorrhage |
3.0% |
Epistaxis |
2.5% |
Haemoptysis |
2.5% |
|